Browse our 650+ Publications​

Latest Publications

Resident and circulating memory T cells persist for years in melanoma patients with durable responses to immunotherapy

Han J, et al.
March 2021
Authors and Affiliates
Jichang Han 1, Yanding Zhao 2, Keisuke Shirai 3,4, Aleksey Molodtsov 1, Fred W. Kolling 3, Jan L. Fisher 4, Peisheng Zhang 3, Shaofeng Yan 5, Tyler G. Searles 3, Justin M. Bader 3, Jiang Gui 3, Chao Cheng 6, Marc S. Ernstoff 7, Mary Jo Turk 1,3 and Christina V. Angeles 3,8,9,10; 1 Departments of Microbiology and Immunology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA 2 Departments of Molecular and Systems Biology, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA 3 Norris Cotton Cancer Center, The Geisel School of Medicine at Dartmouth, Lebanon, NH, USA 4 Departments of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA 5 Departments of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA 6 Baylor School of Medicine, Houston, TX, USA 7 Roswell Park Cancer Institute, Buffalo, NY, USA 8 Departments of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA 9 University of Michigan Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA 10 Department of Surgery, University of Michigan, Ann Arbor, MI, USA

Predicting recognition between T cell receptors and epitopes with TCRGP

Jokinen E, et al.
March 2021
Authors and Affiliates
Emmi Jokinen 1, Jani Huuhtanen 2,3, Satu Mustjoki 2,3,4, Markus Heinonen 1,5, Harri Lähdesmäki 1; 1 Department of Computer Science, Aalto University, Espoo, Finland. 2 Translational Immunology Research program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. 3 Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. 4 iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland. 5 Helsinki Institute for Information Technology, Espoo, Finland.

Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment

Aghel N, et al.
March 2021
Authors and Affiliates
Nazanin Aghel 1,2, Dakota Gustafson 3,4, Ashley Di Meo 5, Milena Music 5, Ioannis Prassas 5, Michael A. Seidman 6, Aaron R. Hansen 7, Paaladinesh Thavendiranathan 1,8, Eleftherios P. Diamandis 4,5,9,10, Diego Delgado 1 and Jason E. Fish 1,3,4; 1 Division of Cardiology, Peter Munk Cardiac Centre, Toronto General Hospital, Ted Rogers Program in Cardiotoxicity Prevention, University Health Network, Toronto, ON, Canada 2 Division of Cardiology, Cardio-oncology Program, Juravinski Hospital, McMaster University, Hamilton, ON, Canada 3 Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada 4 Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada 5 Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, ON, Canada 6 Laboratory Medicine Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada 7 Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada 8 Joint Division of Medical Imaging, Toronto General Hospital, University Health Network, Toronto, ON, Canada 9 Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, ON, Canada 10 Department of Clinical Biochemistry, University Health Network, Toronto, ON, Canada

Utility of high-throughput sequencing of T-cell receptor rearrangements in assessing treatment response in patients with mature T-cell lymphoma

Phull PM, et al.
precision cancer medicine
March 2021
Authors and Affiliates
Pooja M. Phull 1, Carlyn R. Tan 1, Henry C. Fung 1, Paul A. Fields 2, Yang Liu 1, Jasmine Zain 3, Nathan H. Fowler 4, R. Katherine Alpaugh 5, Yasuhiro Ok i4, Stefan K. Barta 1,6; 1 Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA 2 Adaptive Biotechnologies, Seattle, WA, USA 3 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Cancer Center, Duarte, CA, USA 4 Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA 5 Protocol Support Laboratory, Fox Chase Cancer Center, Philadelphia, PA, USA 6 Department of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA, USA

Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma

Smith C. et al.
npj precision oncology
March 2021
Authors and Affiliates
Corey Smith 1, Margaret McGrath 2, Michelle A Neller 1, Katherine K Matthews 1, Pauline Crooks 1, Laetitia Le Texier 1, Benedict Panizza 2, Sandro Porceddu 2, Rajiv Khanna 3; 1 QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumour Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. 2 Princess Alexandra Hospital, Faculty of Medicine, University of Queensland, Brisbane, Australia. 3 QIMR Berghofer Centre for Immunotherapy and Vaccine Development and Tumour Immunology Laboratory, Department of Immunology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia. rajiv.khanna@qimr.edu.au.

A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation

Lazarian G., et al.
Cancer Cell
March 2021
Authors and Affiliates
Gregory Lazarian 1, Shanye Yin 2, Elisa Ten Hacken 2, Tomasz Sewastianik 3, Mohamed Uduman 4, Alba Font-Tello 5, Satyen H Gohil 6, Shuqiang Li 7, Ekaterina Kim 8, Heather Joyal 9, Leah Billington 9, Elizabeth Witten 9, Mei Zheng 10, Teddy Huang 11, Mariano Severgnini 12, Valerie Lefebvre 13, Laura Z Rassenti 14, Catherine Gutierrez 2, Katia Georgopoulos 15, Christopher J Ott 16, Lili Wang 17, Thomas J Kipps 18, Jan A Burger 8, Kenneth J Livak 19, Donna S Neuberg 20, Fanny Baran-Marszak 21, Florence Cymbalista 21, Ruben D Carrasco 22, Catherine J Wu 23; 1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; INSERM, U978, Université Paris 13, Bobigny, France; Laboratoire d'Hématologie, APHP Hôpital Avicenne, Bobigny, France. 2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA. 3 Harvard Medical School, Boston, MA, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Experimental Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland. 4 Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 5 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA. 6 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Academic Haematology, University College London, London, UK. 7 Broad Institute of MIT and Harvard, Cambridge, MA, USA; Translational Immunogenomics Lab, Dana-Farber Cancer Institute, Boston, MA, USA. 8 Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, TX, USA. 9 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 10 Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 11 Broad Institute of MIT and Harvard, Cambridge, MA, USA. 12 Center for Immuno-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA. 13 Laboratoire d'Hématologie, APHP Hôpital Avicenne, Bobigny, France. 14 Moores Cancer Center, University of California, San Diego, USA. 15 Cutaneous Biology Research Center, Massachusetts General Hospital, Charlestown, MA, USA. 16 Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 17 Department of Systems Biology, Beckman Research Institute, City of Hope National Comprehensive Cancer Center, Monrovia, CA, USA. 18 Division of Hematology-Oncology, Department of Medicine, Moores Cancer Center, University of California, San Diego, USA. 19 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA. 20 Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA. 21 INSERM, U978, Université Paris 13, Bobigny, France; Laboratoire d'Hématologie, APHP Hôpital Avicenne, Bobigny, France. 22 Harvard Medical School, Boston, MA, USA; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA; Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA. 23 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA; Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA. Electronic address: cwu@partners.org.

Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery

Chiou S., et al.
Immunity
March 2021
Authors and Affiliates
Shin-Heng Chiou 1, Diane Tseng 2, Alexandre Reuben 3, Vamsee Mallajosyula 1, Irene S Molina 1, Stephanie Conley 4, Julie Wilhelmy 5, Alana M McSween 1, Xinbo Yang 6, Daisuke Nishimiya 6, Rahul Sinha 4, Barzin Y Nabet 7, Chunlin Wang 1, Joseph B Shrager 8, Mark F Berry 9, Leah Backhus 8, Natalie S Lui 8, Heather A Wakelee 10, Joel W Neal 10, Sukhmani K Padda 2, Gerald J Berry 11, Alberto Delaidelli 12, Poul H Sorensen 12, Elena Sotillo 13, Patrick Tran 13, Jalen A Benson 9, Rebecca Richards 14, Louai Labanieh 15, Dorota D Klysz 13, David M Louis 1, Steven A Feldman 13, Maximilian Diehn 16, Irving L Weissman 4, Jianjun Zhang 17, Ignacio I Wistuba 18, P Andrew Futreal 19, John V Heymach 3, K Christopher Garcia 20, Crystal L Mackall 21, Mark M Davis 22; 1 Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA 94305, USA. 2 Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305, USA. 3 Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA. 4 Institute for Stem Cell Biology and Regenerative Medicine Institute, Stanford University, Stanford, CA 94305, USA. 5 Stanford Genome Technology Center, Stanford University, Stanford, CA 94305, USA. 6 Department of Molecular and Cellular Physiology and Structural Biology, Stanford University, Stanford, CA 94305, USA. 7 Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA. 8 Department of Cardiothoracic Surgery - Thoracic Surgery, Stanford University, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford, CA 94305, USA. 9 Department of Cardiothoracic Surgery - Thoracic Surgery, Stanford University, Stanford, CA 94305, USA. 10 Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford, CA 94305, USA. 11 Department of Pathology, Stanford University, Stanford, CA 94305, USA. 12 Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada. 13 Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA. 14 Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA; Department of Pediatrics, Stanford University, Stanford, CA 94305, USA. 15 Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA; Department of Bioengineering, Stanford University, Stanford, CA 94305, USA. 16 Institute for Stem Cell Biology and Regenerative Medicine Institute, Stanford University, Stanford, CA 94305, USA; Department of Radiation Oncology, Stanford University, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford, CA 94305, USA. 17 Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Genomic Medicine, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA. 18 Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA. 19 Department of Genomic Medicine, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA. 20 Department of Molecular and Cellular Physiology and Structural Biology, Stanford University, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. 21 Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA; Department of Pediatrics, Stanford University, Stanford, CA 94305, USA; Department of Medicine, Stanford University, Stanford, CA 94305, USA. 22 Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA 94305, USA; Howard Hughes Medical Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Department of Microbiology and Immunology, Stanford University, Stanford, CA 94305, USA. Electronic address: mmdavis@stanford.edu.
Previous Next